Aug 2026· Oncology Report· Vol 56· 0 citations· 110 references
Medicine
TL;DR
The glutamine-ammonium axis is highlighted as a promising but largely untapped therapeutic target requiring translation into clinical investigation, including combination strategies with immunotherapy.
Abstract
Prostate cancer progression is typically driven by metabolic reprogramming and immune evasion, yet the interface between these processes remains incompletely understood. Dysregulated glutamine metabolism extends beyond bioenergetic support to actively shape antitumor immunity through nutrient competition and ammonium accumulation within the tumor microenvironment. Ammonium, traditionally viewed as a toxic waste product, is a critical immunosuppressive metabolite that impairs T cell function and promotes macrophage M2 polarization. The present review aimed to summarize the bidirectional crosstalk between tumor metabolism and immune cells, with emphasis on how metabolic alterations drive therapeutic resistance. While the majority of evidence supporting this axis derives from preclinical models, the present review highlights the glutamine-ammonium axis as a promising but largely untapped therapeutic target requiring translation into clinical investigation, including combination strategies with immunotherapy.
Mechanisms underlying the immunosuppressive microenvironment in hepatocellular carcinoma (HCC) extend beyond immune checkpoints to include metabolic competition. Here, we identify a metabolic evasion pathway driven by SLC1A5 overexpression, which enables HCC cells to sequester glutamine from the tumor microenvironmen...
Jingjing Nian, Zi-Ran Wang, Shi-Yi Chen et al.· Cell Death & Disease· 0 citations
This paper systematically reviews the biological functions of glutamine metabolism, delves into its relationships with various types of regulated cell death, elucidates its role in immune microenvironment, and summarizes the current application progress of anti-tumor drugs targeting glutamine metabolism.
It is confirmed that amino acid metabolism acts as a core driver of tumor proliferation, immune evasion and therapeutic resistance, and the potential of metabolic-targeted strategies in overcoming drug resistance and improving clinical efficacy is clarified.
Xuan-Hao Wu, Xiao-Dan Mao· International Journal of Med...· 0 citations
Glioblastoma (GB) is characterized by aggressive progression and frequent recurrence despite temozolomide (TMZ)-based therapy. Although resistance is commonly linked to DNA repair mechanisms, these pathways do not fully explain tumor persistence under therapeutic stress. Accumulating evidence suggests that metabolic re...
Mehdi Eshraghi, Ivan Iurchenko, Amir Barzegar Behrooz· Biochimica et Biophysica Act...· 0 citations
Metabolic reprogramming is a fundamental regulator of immune cell fate and function in the tumor microenvironment (TME), though the relative contributions of individual metabolic pathways vary across immune cell subsets, tumor types, and disease stages. Competition for nutrients, hypoxia, and the accumulation of immuno...
Yi-Qing Jiang, Yan-Ling Wu, Tian-Lei Ying· Cancer Biome and Targeted Th...· 0 citations
Emerging evidence demonstrates that tumor metabolic reprogramming not only supports tumor-cell proliferation but also promotes the establishment of an immunosuppressive tumor microenvironment (TME) by altering nutrient competition and metabolite accumulation. Therefore, metabolic reprogramming and immune evasion should...
Hai-Lun Wang, Han-Yuan Zhao, Xue-Lu Pu et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
